A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
This study is the first-in-human (FIH) trial of QLS2406-1 injection, a randomized, double-blind, placebo-controlled Phase I clinical study consisting of two parts.
Part A is a single ascending dose (SAD) design with doses escalated sequentially per the predefined escalation scheme. Eight overweight or obese participants will be enrolled in each cohort and randomized at a 6:2 ratio to receive QLS2406-1 or placebo. Part B is a multiple ascending dose (MAD) study in obese participants. Two dosing frequencies are to be explored: once weekly (QW), and once every two weeks (Q2W). For the QW schedule, 15 obese participants will be randomized at a 12:3 ratio to receive QLS2406-1 or placebo. For the Q2W schedule, 12 participants will be randomized at a 10:2 ratio to receive QLS2406-1 or placebo.
The primary objective is to evaluate the safety and tolerability of this new long-acting quad-agonist QLS2406-1. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate if the long-acting four-receptor agonist has possible pharmacodynamic effects measured as changes in weight, waist circumference and lipid profiles.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: qian zhang, Master of Medicine
- Puhelinnumero: 86-0551-65997163
- Sähköposti: Zhangqian@ahmu.edu.com
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Part A
- Aged 18 to 55 years (inclusive) at screening, with no restriction on gender;
- At screening, female subjects have a body weight ≥50.0 kg, male subjects have a body weight ≥55.0 kg, and BMI ranges from 24.0 kg/m² to 32.0 kg/m² (inclusive);
- Subjects are in good health as comprehensively assessed by the Investigator, with no clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), abdominal ultrasonography, clinical laboratory tests, etc.;
- Female subjects have no plan for pregnancy or oocyte donation from screening to 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan for fathering a child or sperm donation from the first dose to 6 months after the last dose and agree to use at least one highly effective contraceptive method to avoid partner pregnancy.
- Subjects understand the trial procedures and potential risks before enrollment and voluntarily provide written informed consent
-
Part B
- Aged 18 to 65 years (inclusive) at screening, regardless of gender;
- BMI at screening ranges from 28.0 kg/m² to 40.0 kg/m² (inclusive);
- Female subjects have no plan for pregnancy or oocyte donation from screening through 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan to father a child or donate sperm from the first dose through 6 months after the last dose and agree to use at least one highly effective contraceptive method to prevent partner pregnancy;
- Subjects understand the trial procedures and potential adverse reactions prior to enrollment and voluntarily provide written informed consent;
- Body weight fluctuation within 12 weeks before screening is ≤5% (self-reported).
Exclusion Criteria:
-
Overweight or obesity known to be caused by monogenic mutation, other diseases (e.g., Cushing syndrome, hypothalamic obesity) or medications;
-
History of any severe clinical disease, or clinically significant cardiovascular, metabolic, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, gynecologic, neurologic, psychiatric, musculoskeletal, hematologic disorders or malignancy within 24 weeks prior to randomization;
-
Known history of psychiatric disorders such as depression, schizophrenia, bipolar disorder, etc.;
-
Known history of gastrointestinal disease or surgery that may affect safety assessment, or planned surgery during the study;
-
Personal or family history of medullary thyroid carcinoma, C-cell hyperplasia of the thyroid, multiple endocrine neoplasia type 2; history of thyroid surgery, ¹³¹I therapy, or thyroid nodules of unknown etiology;
-
History of hypoglycemia within 24 weeks prior to randomization;
-
12-lead ECG at screening with heart rate >100 bpm or <50 bpm, second- or third-degree atrioventricular block, prolonged QTcF (>450 ms for males, >470 ms for females), or other clinically significant ECG abnormalities judged unsuitable by the Investigator; or family history of long QT syndrome or Brugada syndrome;
-
History of hypertension with ongoing antihypertensive therapy, or screening SBP ≥160 mmHg or DBP ≥90 mmHg;
-
Use of any drugs, products or non-pharmacologic therapies (other than investigational product) affecting glucose metabolism, lipid metabolism or body weight assessment within 12 weeks before screening;
-
Any screening laboratory value meeting any of the following criteria, including but not limited to:
- Serum amylase or serum lipase >1.5 × upper limit of normal (ULN);
- Fasting glucose abnormality or glycated hemoglobin (HbA1c) ≥6.5%;
- Calcitonin >20 ng/L;
- TG ≥5.65 mmol/L (500 mg/dL);
- E value ≥12.0 kPa (FibroScan) (Part B only)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Kolminkertaistaa
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Part A Cohort 1
SAD dose 1 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part A Cohort 2
SAD dose 2 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part A Cohort 3
SAD dose 3 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part A Cohort 4
SAD dose 4 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part A Cohort 5
SAD dose 5 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part B Cohort 1
MAD dose 1 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part B Cohort 2
MAD dose 2 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part B Cohort 3
MAD dose 3 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part B Cohort 4
MAD dose 4 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part B Cohort 5
MAD dose 5 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Kokeellinen: Part B Cohort 6
MAD dose 6 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Adverse Events (AEs)
Aikaikkuna: Baseline to Day 71
|
A summary of AEs, SAEs, and other non-serious adverse events following single subcutaneous injection of QLS2406-1 |
Baseline to Day 71
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Cmax of QLS2406-1
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Maximum observed plasma concentration of QLS2406-1 |
From baseline to the end of treatment (up to Day 71)
|
|
AUC of QLS2406-1
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Area under the serum concentration-time curve (AUC) |
From baseline to the end of treatment (up to Day 71)
|
|
Tmax of QLS2406-1
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Evaluate the time to reach peak plasma concentration of QLS2406-1 |
From baseline to the end of treatment (up to Day 71)
|
|
Half-life of QLS2406-1
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Evaluate the time required for the plasma concentration of QLS2406-1 to decrease by 50% |
From baseline to the end of treatment (up to Day 71)
|
|
% Change From Baseline in Body Weight
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Weight |
From baseline to the end of treatment (up to Day 71)
|
|
% Change From Baseline in Fasting Lipid Concentration
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Fasting lipid concentration |
From baseline to the end of treatment (up to Day 71)
|
|
Incidence of Anti-drug Antibodies (ADA)
Aikaikkuna: From baseline to the end of treatment (up to Day 71)
|
Assessment of the incidence of anti-drug antibodies (ADA) developed against QLS2406-1 after dosing |
From baseline to the end of treatment (up to Day 71)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- QLS2406-1-101
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .